PURPOSE: Effective biomarkers for malignant mesothelioma (MM) are needed for clinical management and the development of mesothelin-targeted therapies. We evaluated serum megakaryocyte potentiating factor (MPF) as a biomarker predictive of treatment outcome in patients with MM and for developing mesothelin-targeted therapies. MATERIALS AND METHODS: Serial serum samples from patients with MM in two clinical trials of an antimesothelin immunotoxin were tested with our clinically validated MPF assay. Correlative studies were performed to determine the test effectiveness in treatment monitoring and outcome prediction. MPF was further evaluated for an association with response to an antimesothelin therapy and for disease monitoring. RESULTS: There was a significant reduction of serum MPF in patients with elevated baseline and radiologic response, with an average change from -52% to -78% after one to six cycles. Using a -50% change as the cutoff, patients with MM with positive MPF response had significantly improved progression-free survival (P < .001), with the median extended from 1.9 to 11.3 months. These patients with MPF response further exhibited improved overall survival (P = .004), with the median extended from 8.8 to 22.3 months. In patients with refractory MM, there was an association between elevated pretreatment serum MPF and radiologic response to an antimesothelin therapy (P = .033). Furthermore, in these response patients, serum MPF was monitored between 32.2 and 63.8 months and was found to reflect treatment response and disease progression. CONCLUSION: At a cutoff of -50% change after receiving systemic therapies, a reduction in MPF was associated with improved clinical outcome, both progression-free survival and overall survival. An elevated baseline serum MPF was associated with a response to an antimesothelin therapy in patients with refractory MM; however, this finding needs to be confirmed in another study.
PURPOSE: Effective biomarkers for malignant mesothelioma (MM) are needed for clinical management and the development of mesothelin-targeted therapies. We evaluated serum megakaryocyte potentiating factor (MPF) as a biomarker predictive of treatment outcome in patients with MM and for developing mesothelin-targeted therapies. MATERIALS AND METHODS: Serial serum samples from patients with MM in two clinical trials of an antimesothelin immunotoxin were tested with our clinically validated MPF assay. Correlative studies were performed to determine the test effectiveness in treatment monitoring and outcome prediction. MPF was further evaluated for an association with response to an antimesothelin therapy and for disease monitoring. RESULTS: There was a significant reduction of serum MPF in patients with elevated baseline and radiologic response, with an average change from -52% to -78% after one to six cycles. Using a -50% change as the cutoff, patients with MM with positive MPF response had significantly improved progression-free survival (P < .001), with the median extended from 1.9 to 11.3 months. These patients with MPF response further exhibited improved overall survival (P = .004), with the median extended from 8.8 to 22.3 months. In patients with refractory MM, there was an association between elevated pretreatment serum MPF and radiologic response to an antimesothelin therapy (P = .033). Furthermore, in these response patients, serum MPF was monitored between 32.2 and 63.8 months and was found to reflect treatment response and disease progression. CONCLUSION: At a cutoff of -50% change after receiving systemic therapies, a reduction in MPF was associated with improved clinical outcome, both progression-free survival and overall survival. An elevated baseline serum MPF was associated with a response to an antimesothelin therapy in patients with refractory MM; however, this finding needs to be confirmed in another study.
Authors: Kevin Hollevoet; Kristiaan Nackaerts; Robert Gosselin; Walter De Wever; Lionel Bosquée; Paul De Vuyst; Paul Germonpré; Eliane Kellen; Catherine Legrand; Yoshiro Kishi; Joris R Delanghe; Jan P van Meerbeeck Journal: J Thorac Oncol Date: 2011-11 Impact factor: 15.609
Authors: Gregory L Beatty; Andrew R Haas; Marcela V Maus; Drew A Torigian; Michael C Soulen; Gabriela Plesa; Anne Chew; Yangbing Zhao; Bruce L Levine; Steven M Albelda; Michael Kalos; Carl H June Journal: Cancer Immunol Res Date: 2014-02 Impact factor: 11.151
Authors: Paul Wheatley-Price; Boming Yang; Demetris Patsios; Devalben Patel; Clement Ma; Wei Xu; Natasha Leighl; Ronald Feld; B C John Cho; Brenda O'Sullivan; Heidi Roberts; Ming Sound Tsao; Martin Tammemagi; Masaki Anraku; Zhuo Chen; Marc de Perrot; Geoffrey Liu Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: Rob J van Klaveren; Joachim G J V Aerts; Hein de Bruin; Guiseppe Giaccone; Christian Manegold; Jan P van Meerbeeck Journal: Lung Cancer Date: 2004-01 Impact factor: 5.705
Authors: Raffit Hassan; Elad Sharon; Anish Thomas; Jingli Zhang; Alexander Ling; Markku Miettinen; Robert J Kreitman; Seth M Steinberg; Kevin Hollevoet; Ira Pastan Journal: Cancer Date: 2014-07-02 Impact factor: 6.921